Diphtheria tetanus pertussis-hepatitis B vaccine - GlaxoSmithKline

Drug Profile

Diphtheria tetanus pertussis-hepatitis B vaccine - GlaxoSmithKline

Alternative Names: Diphtheria-tetanus-pertussis-hep B vaccine (Tritanrix-HepB) - GlaxoSmithKline; DPT + Hepa B vaccine - GlaxoSmithKline; DTPw-HBV vaccine - GlaxoSmithKline; Tritanrix HB - GlaxoSmithKline; Tritanrix HepB; Tritanrix-HepB

Latest Information Update: 22 Jan 2014

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Bacterial vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Hepatitis B; Pertussis; Tetanus

Most Recent Events

  • 20 Dec 2013 The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopts a positive scientific opinion in accordance with Article 58 of Regulation (EC) No 726/2004 for Tritanrix® HB for immunisation against diphtheria, tetanus pertussis and hepatitis B in infants from 6 weeks onwards
  • 05 May 2011 Launched for Tetanus in Vietnam (IM)
  • 05 May 2011 Launched for Pertussis in Vietnam (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top